Gulim Murzakanova

• Lahmami, Gulim; Räisänen, Sari; Jacobsen, Anne Flem; Yli, Branislava Markovic; Tingleff, Tiril & Laine, Katariina (2023). Trends in Term Intrapartum Stillbirth in Norway. JAMA Network Open. ISSN 2574-3805. 6(9). doi: 10.1001/jamanetworkopen.2023.34830. Fulltekst i vitenarkiv
• Tingleff, Tiril; Räisänen, Sari; Vikanes, Åse Vigdis; Sandvik, Leiv; Sugulle, Meryam & Lahmami, Gulim [Vis alle 7 forfattere av denne artikkelen] (2022). Different pathways for preterm birth between singleton and twin pregnancies: a population-based registry study of 481 176 nulliparous women. BJOG: An International Journal of Obstetrics and Gynaecology. ISSN 1470-0328. s. 1–9. doi: 10.1111/1471-0528.17344. Fulltekst i vitenarkiv
• Berge, Magnus & Lahmami, Gulim (2022). Matavhengig treningsindusert anafylaksi under graviditet. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 142(11). doi: 10.4045/tidsskr.21.0832. Fulltekst i vitenarkiv
• Tingleff, Tiril; Vikanes, A.; Räisänen, S.; Sandvik, Leiv; Lahmami, Gulim & Laine, Katariina (2021). Risk of preterm birth in relation to history of preterm birth: a population-based registry study of 213 335 women in Norway. BJOG: An International Journal of Obstetrics and Gynaecology. ISSN 1470-0328. s. 1–8. doi: 10.1111/1471-0528.17013. Fulltekst i vitenarkiv
• Lahmami, Gulim; Räisänen, Sari; Jacobsen, Anne Flem; Sole, Kristina Baker; BJARKØ, LISA & Laine, Katariina (2020). Adverse perinatal outcomes in 665,244 term and post-term deliveries—a Norwegian population-based study. European Journal of Obstetrics, Gynecology, and Reproductive Biology. ISSN 0301-2115. 247, s. 212–218. doi: 10.1016/j.ejogrb.2020.02.028.
• Laine, Katariina; Lahmami, Gulim; Sole, Kristina Baker; Pay, Aase Serine Devold; Heradstveit, Siri & Räisänen, Sari (2019). Prevalence and risk of pre-eclampsia and gestational hypertension in twin pregnancies: A population-based register study. BMJ Open. ISSN 2044-6055. 9:e029908(7), s. 1–8. doi: 10.1136/bmjopen-2019-029908. Fulltekst i vitenarkiv Vis sammendrag

  Objectives The aim of this study was to assess the prevalence and risk of pre-eclampsia and gestational hypertension in twin pregnancies compared with singleton pregnancies. Design Population-based cohort study. Setting Medical Birth Registry of Norway and Statistics Norway. Participants 929 963 deliveries with 16 174 twin pregnancies in 1999–2014. Methods Pre-eclampsia prevalences in twin and singleton pregnancies were described in percentages. Multivariable regression analyses were performed to assess the risks of pre-eclampsia and gestational hypertension in twin pregnancies compared with those in singleton pregnancies, adjusted for previously known risk factors. Primary and secondary outcome measures Prevalence and risk of pre-eclampsia and gestational hypertension. Results The prevalence of pre-eclampsia in the study population was 3.7% (3.4% in singleton pregnancies, 11.8% in twin pregnancies (p=0.001)). The OR for pre-eclampsia in twin pregnancies was three to fourfold compared with singleton pregnancies (OR 3.78; 95% CI 3.59 to 3.96). After adjustment for known risk factors, twin pregnancy remained an independent risk factor for pre-eclampsia (adjusted OR 4.07; 95% CI 3.65 to 4.54). The prevalence of gestational hypertension was 1.7% in women with singleton pregnancies and 2.2% in those with twin pregnancies (OR 1.27; 95% CI 1.14 to 1.41). After adjustment for known risk factors, gestational hypertension was not significantly associated with twin pregnancy. Conclusions The risk of pre-eclampsia in twin pregnancies was three to fourfold compared with singleton pregnancies, regardless of maternal age, parity, educational level, smoking, maternal comorbidity or in vitro fertilisation. The risk of gestational hypertension was not increased in women with twin pregnancies after adjustment for the main risk factors. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

• Pettersen-Dahl, Anita; Lahmami, Gulim; Sandvik, Leiv & Laine, Katariina (2017). Maternal body mass index as a predictor for delivery method. Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349. 97(2), s. 212–218. doi: 10.1111/aogs.13265.
• Vanky, Eszter; Stridsklev, Solhild; Skogøy, Kristin; Kleggetveit, Odrun; Hjelle, Sissel & Von, Brandis Philip [Vis alle 17 forfattere av denne artikkelen] (2011). PCOS - what matters in early pregnancy? - data from a cross-sectional, multicenter study. Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349. 90(4), s. 398–404. doi: 10.1111/j.1600-0412.2010.01064.x. Vis sammendrag

  OBJECTIVE: To describe patient characteristics according to different diagnostic criteria in early pregnancy, in women with polycystic ovary syndrome (PCOS). DESIGN: Descriptive, cross-sectional study of 257 women with PCOS in the first trimester of pregnancy. SETTING: Data from a multicenter trial at the time of inclusion. POPULATION: 257 PCOS women with singleton pregnancies. METHODS: Investigator-administrated questionnaires were filled out. Clinical examination was performed by the investigators. Fasting blood samples were collected. MAIN OUTCOME MEASURES: Biometric data, androgens, glucose and insulin levels. RESULTS: Women who met the National Institutes of Health (NIH) criteria for PCOS had higher body mass index (BMI), testosterone, dehydroepiandrostenedione, free testosterone index (FTI) and insulin levels compared with those who only met the Rotterdam consensus criteria. Adjusted for age and BMI, only testosterone and FTI were higher in those who met the NIH criteria. BMI was a strong, independent predictor of both systolic and diastolic blood pressure in early PCOS pregnancy, while both FTI and fasting insulin were independent predictors of systolic blood pressure. Twenty-two (9%) of the participants had gestational diabetes mellitus in the first trimester of pregnancy. CONCLUSIONS: In the first trimester, PCOS women diagnosed according to NIH criteria were more metabolically and endocrinologically abnormal compared with those who only met the Rotterdam consensus criteria. BMI and FTI were independent predictive factors for blood pressure. There was a high prevalence of gestational diabetes mellitus in early PCOS pregnancies.

• Vanky, Eszter; Stridsklev, Solhild; Heimstad, Runa Kristine; Romundstad, Pål Richard; Skogøy, Kristin & Kleggetveit, Odrun [Vis alle 19 forfattere av denne artikkelen] (2010). Metformin Versus Placebo from First Trimester to Delivery in Polycystic Ovary Syndrome: A Randomized, Controlled Multicenter Study. Journal of Clinical Endocrinology and Metabolism (JCEM). ISSN 0021-972X. 95(12), s. E448–E455. doi: 10.1210/jc.2010-0853. Vis sammendrag

  CONTEXT: Metformin is widely prescribed to pregnant women with polycystic ovary syndrome (PCOS) in an attempt to reduce pregnancy complications. Metformin is not approved for this indication, and evidence for this practice is lacking. OBJECTIVES: Our objective was to test the hypothesis that metformin, from first trimester to delivery, reduces pregnancy complications in women with PCOS. DESIGN AND SETTING: We conducted a randomized, placebo-controlled, double-blind, multicenter study at 11 secondary care centers. PARTICIPANTS: The participants were 257 women with PCOS, in the first trimester of pregnancy, aged 18-42 yr. INTERVENTION: We randomly assigned 274 singleton pregnancies (in 257 women) to receive metformin or placebo, from first trimester to delivery. MAIN OUTCOME MEASURES: The prevalence of preeclampsia, gestational diabetes mellitus, preterm delivery, and a composite of these three outcomes is reported. RESULTS: Preeclampsia prevalence was 7.4% in the metformin group and 3.7% in the placebo group (3.7%; 95% CI, -1.7-9.2) (P=0.18). Preterm delivery prevalence was 3.7% in the metformin group and 8.2% in the placebo group (-4.4%; 95%, CI, -10.1-1.2) (P=0.12). Gestational diabetes mellitus prevalence was 17.6% in the metformin group and 16.9% in the placebo group (0.8%; 95% CI, -8.6-10.2) (P=0.87). The composite primary endpoint prevalence was 25.9 and 24.4%, respectively (1.5%; 95% CI, -8.9-11.3) (P=0.78). Women in the metformin group gained less weight during pregnancy compared with those in the placebo group. There was no difference in fetal birth weight between the groups. CONCLUSIONS: Metformin treatment from first trimester to delivery did not reduce pregnancy complications in PCOS.

Se alle arbeider i Cristin